← Back to Patent Explorer
US4562069A Expired / Lapsed US ⏱️ 0.0 years remaining

Two-phase formulation

Assignee: Bayer AG
•
Filing: 1984-05-02
•
Granted: 1985-12-31
•
Expires: 2004-05-02
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract In the treatment of cardiovascular and coronary disorders by administering to a patent suffering therefrom a solid preparation comprising nifedipine, the improvement which comprises administering such nifedipine in the form of a solid two-phase medicament formulation comprising a nifedipine coprecipitate, in which the nifedipine is present in a non-crystalline form, and crystalline nifedipine, whereby the nifedipine rapidly enters the blood stream in a relatively high concentration which is maintained for a relatively long time.

Inventors

  • 👤 Ahmed Hegasy
  • 👤 Roland Rupp
  • 👤 Klaus-Dieter Ramsch
  • 👤 Helmut Luchtenberg

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 20:04
CPC Classifications
C; C07; C07D; C07D211/00; C07D211/04; C07D211/80; C07D211/84; C07D211/90; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K9/00; A61K9/14; A61K9/141; A61K9/146

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 22 words
A solid two-phase medicament formulation comprising a nifedipine coprecipitate, in which the nifedipine is present in a non-crystalline form, and crystalline nifedipine.
Claim 2
Dependent Claim 22 words
A solid two-phase medicament formulation comprising a nifedipine coprecipitate, in which the nifedipine is present in a non-crystalline form, and crystalline nifedipine.
Claim 3
Dependent Claim 50 words
A two-phase medicament formulation according to claim 1, comprising a nifedipine coprecipitate, in which about 1 part by weight of nifedipine is present in a dissolved, non-crystalline form in about 1 to 10 parts by weight of coprecipitate former, and about 1 to 5 parts by weight of crystalline nifedipine.
Claim 4
Dependent Claim 44 words
A two-phase medicament formulation according to claim 1, in the form of tablets, coated tablets or hard gelatin capsules containing a nifedipine coprecipitate which comprises of 1 part by weight of nifedipine and about 1 to 10 parts by weight of a coprecipitate former.
Claim 5
Dependent Claim 24 words
A two-phase medicament formulation according to claim 3, wherein the nifedipine coprecipitate contains about 2 to 6 parts by weight of the coprecipitate former.
Claim 6
Dependent Claim 23 words
A two-phase medicament formulation according to claim 1, where the coprecipitate former is selected from the group comprising polyvinylpyrrollidone, methylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose.
Claim 7
Dependent Claim 23 words
A two-phase medicament formulation according to claim 1, where the crystalline nifedipine has a mean particle diameter of about 10 to 1 μm.
Claim 8
Dependent Claim 25 words
A two-phase medicament formulation according to claim 6, wherein the nifedipine crystals have a specific surface area of about 1.0 to 4.0 m 2 /g.
Claim 9
Dependent Claim 14 words
A two-phase medicament formulation according to claim 2, wherein the coprecipitate former comprises polyvinylpyrrolidone.
Claim 10
Dependent Claim 58 words
In the treatment of cardiovascular and coronary disorders by administering to a patient suffering therefrom a solid preparation comprising nifedipine, the improvement which comprises administering such nifedipine in the form of a formulation according to claim 1, whereby the nifedipine rapidly enters the blod stream in a relatively high concentration which is maintained for a relatively long time.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-12-30 1989-07-01 1989-12-31 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-12-30 1993-07-01 1993-12-31 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-12-30 1997-07-01 1997-12-31 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag